Taros announces appointment of two Scientific Advisors

Taros Chemicals GmbH & Co. KG, “Taros” announced the appointment of Prof. Dr. Herbert Waldmann and Prof. Dr. Axel Kleemann as Scientific Advisors to the Taros Management Board

Dortmund, 07.11.2013 ++++ 
Herbert Waldmann studied chemistry and completed his PhD in organic chemistry in 1985. In 1991 he qualified as professor at the University of Mainz. Shortly thereafter he was appointed professor of organic chemistry at the University of Bonn. In 1993 he became professor of organic chemistry at the University of Karlsruhe. Since 1999 he has headed the Department of Chemical Biology at the Max Planck Institute of Molecular Physiology and, concurrently, has also holds the position of professor of biochemistry at the Technische Universität Dortmund. He has been awarded numerous academic distinctions for his work, including the Otto Bayer Prize and the Max Bergmann Medal.

Axel Kleemann studied Chemistry and received his PhD in Organic Chemistry at the University of Frankfurt in 1967 and joined Degussa AG. In 1976 he became Director of Corporate Organic Research, and in addition in 1983 Director of Pharmaceutical R&D. From 1987 until 2000 he acted as Executive Board Member of ASTA Medica AG with responsibility for R&D, production & engineering, and drug safety. He also served as Chairman of the Supervisory Board of the German Research Center for Biotechnology (GBF, Braunschweig) and held active Board Member positions of various organizations and scientific societies, including GDCh, DPhG, DECHEMA and DIB. He holds a Honorary Professorship at the University of Frankfurt since 1988 and still serves as Member or Chairman of different Supervisory and Scientific Advisory Boards in Fine Chemical or Biotech companies. Kleemann is co-author of the standard reference book “Pharmaceutical Substances”, 5. Ed. (print) and Online version, Thieme Verlag.

Dimitrios Tzalis, Founder and CEO of Taros, said:” “We are very fortunate to have both senior experts, Herbert Waldmann and Axel Kleemann, supporting Taros in shaping the strategic scientific pathway for future successful company growth. My management colleagues and I are looking forward to highly fruitful discussions with them over the next months and years”.

About Taros Chemicals

Taros is a privately owned discovery chemistry company, working with global pharmaceutical, biotech and chemical companies since 1999. Alongside our performance chemicals and material science division, Taros’ drug discovery mission is to create drug candidates as potential new medicines. Taros has a strong scientific track record on many biomolecular targets in all main therapeutic areas and thereby adding considerable value to collaborations from target validation and hit identification to lead generation and optimization. Taros’ core expertise ranges from custom synthesis and process development to modern medicinal and computational chemistry, as well as compound library design and production.
Taros was heading the chemistry efforts of the EUR 196 million funded European Lead Factory (2013-2018) and is currently heading its EUR 36.5 million funded continuation (2019-2022). Moreover, Taros is deeply engaged in other research alliances like the EUR 11 million funded Drug Discovery Hub Dortmund.

Press Contact:
Youri R. Mesmoudi, Executive Vice President, e-mail: innovation |at| taros.de

medicinal chemistry

drug discovery

We are running our own state-of-the-art Drug Discovery Chemistry facilities in Germany with the option for process research chemistry, upscaling, kilolab production…

performance chemicals

material science

We create performance chemicals to enhance new materials, plastics, coatings, dyes & inks, cosmetics, flavors and many more research and industrial applications…


Looks interesting?

As a leading contract research organization in discovery chemistry and custom synthesis, Taros provides comprehensive solutions to meet our clients’ needs from diverse branches and applications

Our experienced chemists practice a pragmatic culture and customer-centric approach in order to exceed project expectations, despite challenges, bridging very narrow timelines. They are trained to consider economic, safety and ecological boundaries and conditions laid out for all stages of the project, starting from the development of synthetic routes to…